Home > Press > Accelrys Releases Enhanced Suite of Accord Cheminformatics Solutions
Accelrys, Inc. (NASDAQ:ACCL) announced the shipment of Accord Database Explorer 3.0, Accord SDK 6.2, and Accord Chemistry Cartridge 6.2, new releases from its Accord family of cheminformatics products for obtaining maximum value from chemical data and for building configurable chemistry-enabled solutions.
Accelrys Releases Enhanced Suite of Accord Cheminformatics Solutions
SAN DIEGO, CA | Posted on January 31st, 2007
Accord Database Explorer 3.0 (ADE 3.0) is a flexible standalone desktop database client that enables users to access multiple databases held locally or centrally and search across them from within a single query. ADE 3.0 contains a new forms-based interface that provides powerful querying, browsing and data editing tools, and also allows users to create their own local databases from SD files for individual project use via a simple wizard.
Accord Software Development Kit (SDK) and Accord Chemistry Cartridge are building blocks for constructing configurable chemistry-enabled software applications.
Accord SDK is a programming toolkit which allows users to develop applications addressing problems as diverse as combinatorial chemistry, property prediction, and database publishing. It can be used to chemistry-enable existing informatics systems or extend the capabilities of other Accord products and solutions. New features in Accord SDK 6.2 include a new CIP calculator and improved performance and support for the Accord Chemistry XML format, a new open and extensible format that enables users to store and transfer chemistry data to third party applications without losing Accord-specific features.
Accord Chemistry Cartridge enhances the power of Oracle for chemical applications by adding a new chemistry data type, which allows users to build solutions that store, index, and search for chemical structures. Accord Chemistry Cartridge 6.2 provides up to 12X faster sub-structure search performance over the previous release, support for multiple processors when performing chemistry searching and other performance enhancements designed to enable users to build high-performance, chemistry-aware applications and solutions.
"These exciting new Accord releases significantly extend and augment the existing Accord family of products and will provide great benefits to our customers," said Dr Frank Brown, Chief Science Officer of Accelrys. "With the launch of ADE 3.0, chemists now have a real alternative to MDL's® ISIS/Base," continued Dr. Brown. "The release of the Accord SDK and Accord Chemistry Cartridge further enhance the capabilities of these robust components by providing enhanced performance and chemistry capabilities to enable our customers to build chemistry-enabled solutions of the highest quality," concluded Dr Brown.
For more information about Accord please visit our website at http://www.accelrys.com .
Accelrys has over twenty years of innovation and technology leadership in delivering software and service solutions that transform discovery and development research. A unique combination of expertise in life and materials science, informatics, and scientific operating platform technologies, lets Accelrys serve a diverse range of clients, including some of the world’s leading pharmaceutical, biotechnology, chemical, and nanotechnology research organizations. Accelrys is headquartered in San Diego, California. For more information about Accelrys, visit its website at http://www.accelrys.com/.
This press release contains forward-looking statements. Such statements, including statements relating to the Company’s products, including the products' features and potential demand therefore, are subject to risks and uncertainties including, but not limited to, the risks that the products will not be timely or successfully completed, developed or achieve market acceptance, demand relating to these products, and other risks and uncertainties described in documents Accelrys has filed with the Securities and Exchange Commission, including its most recent report on Form 10-K and any subsequent interim filings. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Accelrys disclaims any intent or obligation to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
For more information, please click here
Philomena Walsh, (858) 799-5440
Copyright © Business Wire 2007
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Aspen Aerogels Announces $22.5 Million Private Placement May 18th, 2013
NanoInk, Inc. Assets To Be Sold May 18th, 2013
NIA Public Briefing: Nanotechnology and the Council of Europe May 17th, 2013
Scientists capture first direct proof of Hofstadter butterfly effect May 17th, 2013